Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-21
2007-08-21
Wehbe', Anne M. (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
10536274
ABSTRACT:
A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including wounds, inflammatory diseases, critical limb ischemia, ischemia heart diseases, cerebral infarction, diabetic neuropathy, spinal canal stenosis, etc., may be treated by the present methods.
REFERENCES:
patent: 2002/0137707 (2002-09-01), Budker et al.
patent: 2003/0171287 (2003-09-01), Morishita et al.
patent: 2004/0087535 (2004-05-01), Morishita et al.
patent: WO97/40679 (1997-11-01), None
Taniyama et al. Gene Ther. 8:181-189; 2001.
Lubiatowski et al. Plast. Reconstr. Surg. 109:1986-1993; 2002.
Grim et al. JAMA 263; 1990; Abstract.
Niidome et al. Gene Ther. 9:1647-1652; 2002.
Database; BIOSIS Accession No. PREV200200261758; Mar. 2002, and: Taniyama et al.; “Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle”;Gene Therapy9(6):372-380 (Mar. 2002).
Database, BIOSIS Accession No. PREV199800207109; Mar. 31, 1998; and: Baumgartner, Iris et al.; “Constitutive expression of phVEGF165 after intramuscular gene transfer promotes colleteral vessel development in patients with critical limb ischemia”;Circulation97(12):1114-1123 (Mar. 31, 1998).
Database; BIOSIS Accession No. PREV200100114748; Feb. 2001; and: Taniyama, Y. et al.; “Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease”;Gene Therapy8(3):181-189 (Feb. 2001).
Database; BIOSIS Accession No. PREV200200358126; May 2002; and: Comerota, Anthony J. et al.; “Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial”;Journal of Vascular Surgery35(5):930-935 (May 2002).
Database; BIOSIS Accession No. PREV200400009718; Nov. 25, 2003; and: Kazuya, Hiraoka et al.; “Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA”;Circulation108(21):2689-2696 (Nov. 25, 2003).
Feeley, Brian T., et al.; “Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynulceotides to ICAM-1 reduced reperfusion injury in rat cardiac allografts,”Transplantation; Mar. 27, 2000; pp. 1067-1074; 69:6.
Feeley, Brian T., et al.; Database EMBASE; Accession No. EMB-2000145210; “Optimization of ex vivo pressure mediated delivery of antisense oligodeoxynulceotides to ICAM-1 reduces reperfusion injury in rat cardiac allografts,”Transplantation; Mar. 27, 2000.
Hiraoka Kazuya
Kaneda Yasufumi
Morishita Ryuichi
Ogihara Toshio
Yamamoto Seiji
AnGes MG, Inc.
Sajjadi Fereydoun G.
Townsend and Townsend / and Crew LLP
Wehbe Anne M.
LandOfFree
Methods for treating or preventing angiogenesis-dependent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating or preventing angiogenesis-dependent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating or preventing angiogenesis-dependent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3854049